Navigation Links
Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
Date:12/5/2012

n Children with Chronic/Refractory Immune Thrombocytopenia (ITP): Results from an Open-label Phase 1/2 Randomized Double-blind Placebo-controlled Study.
Lead Author: James B. Bussel, Department of Pediatrics, Division of Hematology, Weill Medical College of Cornell University, New York, NY
Abstract No. 621
Oral Presentation: Monday, Dec. 10, 4:30 p.m. – 6:00 p.m. EST, Georgia Ballroom 3, Level 3, Building C

 

  • Integrated Analysis of Long Term Safety in Patients (pts) with Chronic Immune Thrombocytopenia (ITP) Treated with Romiplostim: Results from a Safety Analysis of Pooled Data from ITP Romiplostim Clinical Studies
    Lead Author: Douglas B. Cines, Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA
    Abstract No. 2185
    Poster Presentation: Sunday, Dec. 9, 6:00 p.m. – 8:00 p.m. EST, Hall B1-B2, Level 1, Building B

 

  • A Systematic Literature Review and Meta-Analysis of the Risk of Thromboembolic Events in Patients with Immune Thrombocytopenia (ITP) in Observational Studies: Results from a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Thrombopoietin-receptor Agonists (TPOr)
    Lead Author: Wendy Langeberg, Amgen, Thousand Oaks, CA
    Abstract No. 2187
    Poster Presentation: Sunday, Dec. 9, 6:00 p.m. – 8:00 p.m. EST, Hall B1-B2, Level 1, Building B

 

  • Romiplostim for the Treatment of Adults with Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice – Interim Results From a Large, European, Observational Study
    Lead Author: Dominik Selleslag, Department of Hematology, AZ St-Jan, Brugge, Belgium
    Abstract No. 3316
    Poster Presentation: Monday, Dec. 10, 6:00 p.m. – 8:00 p.m. EST, Hall B1-B2, Level 1, Building B

Nplate in Myelodysp
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
3. Amgen Announces 2012 Third Quarter Dividend
4. Amgen to Present at the Leerink Swann Global Healthcare Conference
5. Amgen to Acquire Micromet
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
8. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
9. Amgen Announces 2012 First Quarter Dividend
10. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
11. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... -- According to the new research ... Wastewater Treatment and Industrial Wastewater Treatment), By Type ... Configuration (Internal/Submerged and External/Sidestream), and By Region-Trends & ... for membrane bioreactor systems is projected to reach ... of 15.28% between 2014 and 2019. ...
(Date:8/18/2014)... Fla. , Aug. 18, 2014 ... biotechnology company whose patented and proprietary technologies are ... other proteins for the bioenergy, bio-based chemical, biopharmaceutical ... has filed a Registration Statement on Form 10 ... "SEC"). Logo - http://photos.prnewswire.com/prnh/20110621/CL06708LOGO ...
(Date:8/18/2014)... 18. August 2014 Vier führende ... internationale klinische Studie auf, in der eine ... soll das Sehvermögen bei allen Entfernungen verbessern, ... möglicherweise keine Lese- oder Gleitsichtbrille mehr benötigen. ... FluidVision Accommodating Intraocular Lens (FluidVision ...
(Date:8/16/2014)... the Walmart Foundation to build a robotic small motors ... costs of goods, allowing those goods to be produced ... , The Walmart U.S. Manufacturing Innovation Grant was part ... seven research and development institutions at the 2014 U.S. ... between Walmart, the U.S. Conference of Mayors and the ...
Breaking Biology Technology:Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3Dyadic International Files Form 10 Registration Statement 2Dyadic International Files Form 10 Registration Statement 3Dyadic International Files Form 10 Registration Statement 4Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4UT Arlington receives Walmart, Walmart Foundation innovation grant 2UT Arlington receives Walmart, Walmart Foundation innovation grant 3
... Today GenVec, Inc. (NASDAQ: GNVC ) announced financial ... 2011.  For the year ended December 31, 2011, the Company ... share, compared with a net loss of $12.3 million, or ... GenVec ended the year with $26.4 million in cash, cash ...
... doubt that the United States will be the No. ... by the year 2020, according to a new national ... deep concerns among Americans about the country,s ability to ... before the next decade. "A lackluster investment in ...
... for someone outside of a specialist field to identify ... data can be bewildering. New research, published in BioMed ... , describes a method of social network analysis, similar ... scientific literature and news articles to identify opinion leaders ...
Cached Biology Technology:GenVec Reports Fourth Quarter and 2011 Year-End Financial Results 2GenVec Reports Fourth Quarter and 2011 Year-End Financial Results 3GenVec Reports Fourth Quarter and 2011 Year-End Financial Results 4GenVec Reports Fourth Quarter and 2011 Year-End Financial Results 5GenVec Reports Fourth Quarter and 2011 Year-End Financial Results 6More than half of Americans doubt US global leadership in 2020 2Social networking shortcut to finding medical experts 2
(Date:8/19/2014)... 2014A new ovoid structure discovered in the Nakhla Martian ... variety of minerals, and shows evidence of undergoing a ... the permafrost and mixing of surface and subsurface fluids. ... analytical studies to determine the origin of this new ... ovoid formed, point to the most likely conclusion, and ...
(Date:8/19/2014)... in French . ... RISKS of physical activity in children,Today the Canadian Society ... of childhood physical activity and published their position and ... Metabolism ( APNM ). This position stand ... of risk of physical activity for children and suggests ...
(Date:8/19/2014)... Daylight was breaking over the central Pacific and ... about a dozen scientists strategized for the day ahead. ... to collect water samples around the southern Line Islands, ... gizmos and delicate machinery strewn throughout the 158-foot research ... research group to bring a DNA sequencer out into ...
Breaking Biology News(10 mins):Life on Mars? Implications of a newly discovered mineral-rich structure 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 3Sequencing at sea 2Sequencing at sea 3
... latch onto blood platelets rapidly create healthy clots and ... hour after injury, new research shows. "We knew ... now we know the bleeding is stopped in time ... professor of biomedical engineering at Case Western Reserve University ...
... polyclonal antibody that blocks follicle-stimulating hormone (FSH) in mice ... prevent or arrest osteoporosis than currently available treatments. ... to show that an injection of a polyclonal antipeptide ... and building bone, say researchers at the Mount Sinai ...
... supports the possibility that daily vitamin D supplementation can reduce ... that will appear in the journal Pediatrics and ... that vitamin D supplementation decreased the risk of respiratory infections ... at the start of the study. "Our randomized ...
Cached Biology News:Nanoparticles added to platelets double internal injury survival rate 2Dual action polyclonal antibody may offer more effective, safer protection against osteoporosis 2Vitamin D supplementation can decrease risk of respiratory infections in children 2Vitamin D supplementation can decrease risk of respiratory infections in children 3
cysteine and glycine-rich protein 2,...
... pan B (B220), 4.5 m, coated ... efficient positive isolation or depletion of ... or lymph node cell suspensions. B220 ... cells and lytically active subsets of ...
Gap junction protein, beta 2, 26kDa (connexin 26) Antigen: Peptide...
NAP-2 (5C7)...
Biology Products: